CP CRANBURY PHARMACEUTICALS Trademark

Trademark Overview

On Tuesday, May 7, 2019, a trademark application was filed for CP CRANBURY PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CP CRANBURY PHARMACEUTICALS trademark a serial number of 88418271. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 25, 2023. This trademark is owned by CRANBURY PHARMACEUTICALS. The CP CRANBURY PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Prescription and non-prescription pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation; dietary supplements; nutritional supplements; vitamins; nutritional supplements in the nature of nutriceuticals for use in treating nutritional deficiencies and as dietary supplements
cp cranbury pharmaceuticals

General Information

Serial Number88418271
Word MarkCP CRANBURY PHARMACEUTICALS
Filing DateTuesday, May 7, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 25, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 29, 2020

Trademark Statements

Description of MarkThe mark consists of interlocked letters "CP" and word portions "CRANBURY PHARMACEUTICALS".
Goods and ServicesPrescription and non-prescription pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation; dietary supplements; nutritional supplements; vitamins; nutritional supplements in the nature of nutriceuticals for use in treating nutritional deficiencies and as dietary supplements
Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 22, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRANBURY PHARMACEUTICALS
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMonmouth Junction, NJ 08852
Party NameCRANBURY PHARMACEUTICALS
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMonmouth Junction, NJ 08852

Trademark Events

Event DateEvent Description
Tuesday, December 26, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 25, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, May 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 17, 2023SOU EXTENSION 5 GRANTED
Friday, May 12, 2023SOU EXTENSION 5 FILED
Friday, May 12, 2023SOU TEAS EXTENSION RECEIVED
Saturday, November 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 3, 2022SOU EXTENSION 4 GRANTED
Thursday, November 3, 2022SOU EXTENSION 4 FILED
Thursday, November 3, 2022SOU TEAS EXTENSION RECEIVED
Friday, April 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 27, 2022SOU EXTENSION 3 GRANTED
Wednesday, April 27, 2022SOU EXTENSION 3 FILED
Wednesday, April 27, 2022SOU TEAS EXTENSION RECEIVED
Thursday, November 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 23, 2021SOU EXTENSION 2 GRANTED
Tuesday, November 23, 2021SOU EXTENSION 2 FILED
Tuesday, November 23, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, June 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 22, 2021SOU EXTENSION 1 GRANTED
Monday, May 24, 2021SOU EXTENSION 1 FILED
Tuesday, June 22, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 27, 2021NOTICE OF REVIVAL - E-MAILED
Thursday, May 27, 2021SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, May 27, 2021PETITION TO REVIVE-GRANTED
Thursday, May 27, 2021TEAS PETITION TO REVIVE RECEIVED
Tuesday, November 24, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 29, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 29, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 9, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 25, 2020EXPARTE APPEAL TERMINATED
Tuesday, August 25, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 20, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 20, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 18, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, August 18, 2020EX PARTE APPEAL-INSTITUTED
Tuesday, August 18, 2020JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, August 18, 2020EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, February 19, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 19, 2020FINAL REFUSAL E-MAILED
Wednesday, February 19, 2020FINAL REFUSAL WRITTEN
Wednesday, January 29, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 29, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 29, 2020ASSIGNED TO LIE
Thursday, January 23, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 25, 2019NOTIFICATION OF PRIORITY ACTION E-MAILED
Thursday, July 25, 2019PRIORITY ACTION E-MAILED
Thursday, July 25, 2019PRIORITY ACTION WRITTEN
Thursday, July 25, 2019PRIORITY ACTION WRITTEN
Monday, July 22, 2019ASSIGNED TO EXAMINER
Thursday, May 23, 2019NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, May 22, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 10, 2019NEW APPLICATION ENTERED

Related Keywords

pharmaceuticals cranbury supplements nutritional disease respiratory symptoms prescription disorder dietary treatment nausea